Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) shot up 5.3% on Tuesday . The company traded as high as $9.00 and last traded at $8.94. 1,412,795 shares were traded during mid-day trading, an increase of 13% from the average session volume of 1,248,410 shares. The stock had previously closed at $8.49.

A number of analysts recently issued reports on CBAY shares. Piper Jaffray Companies reissued an “overweight” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research note on Tuesday, July 25th. Oppenheimer Holdings, Inc. increased their target price on CymaBay Therapeutics from $8.00 to $15.00 and gave the stock an “outperform” rating in a research note on Thursday, July 20th. Ifs Securities reissued a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Leerink Swann started coverage on CymaBay Therapeutics in a research note on Wednesday, August 23rd. They set an “outperform” rating and a $12.00 target price for the company. Finally, Zacks Investment Research cut CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $14.00.

The stock has a 50 day moving average price of $7.21 and a 200-day moving average price of $5.62. The firm’s market capitalization is $388.99 million.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.06). Equities analysts anticipate that CymaBay Therapeutics Inc. will post ($0.82) earnings per share for the current year.

In other news, Director Robert James Wills bought 5,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were bought at an average cost of $6.84 per share, with a total value of $34,200.00. Following the completion of the transaction, the director now directly owns 25,200 shares of the company’s stock, valued at $172,368. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kurt Von Emster sold 211,124 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $8.09, for a total value of $1,707,993.16. The disclosure for this sale can be found here. Insiders have bought 20,000 shares of company stock worth $144,750 over the last ninety days. 15.10% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. Ardsley Advisory Partners raised its position in shares of CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares during the period. Vanguard Group Inc. raised its position in shares of CymaBay Therapeutics by 20.7% during the second quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after purchasing an additional 170,126 shares during the period. Marshall Wace North America L.P. acquired a new position in shares of CymaBay Therapeutics during the second quarter worth approximately $242,000. Bank of New York Mellon Corp raised its position in shares of CymaBay Therapeutics by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 140 shares during the period. Finally, LVM Capital Management Ltd. MI grew its holdings in CymaBay Therapeutics by 100.0% during the second quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 10,000 shares in the last quarter. 25.91% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/12/cymabay-therapeutics-inc-cbay-shares-up-5-3.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Receive News & Stock Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related stocks with our FREE daily email newsletter.